Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
4
×
boston top stories
life sciences
national blog main
national top stories
roche
4
×
biotech
fda
new york blog main
san francisco blog main
boston
boulder/denver blog main
boulder/denver top stories
cancer
companion diagnostic
deals
detroit blog main
detroit top stories
foundation medicine
national
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
advaxis
aimmune therapeutics
alder biopharmaceuticals
alexander hardy
andrew oxtoby
babies
biopharma
blueprint medicines
What
medicine
4
×
big
billion
fda
recently
roche
second
acquire
agreed
approval
approved
betting
bio
biopharma
bosley's
bosley’s
bridge
broad
bucks
cancer
cas
ceo
confidence
crime
crispr
deal
deeper
departure
didn’t
dna
drug
duchenne
editas
exit
fingerprint
foundation
gain
gene
genentech
genetic
Language
unset
Current search:
roche
×
medicine
×
" boston blog main "
×
@xconomy.com
4 years ago
Roche Puts Up Historic $1.15B for Sarepta Duchenne Gene Therapy Deal
@xconomy.com
5 years ago
Bio Roundup: Bosley’s Editas Exit, Bridge Bucks, CRISPR Crime & More
@xconomy.com
5 years ago
Genetic Medicine: FDA OKs 2nd Cancer Drug that Targets DNA, not Tissues
@xconomy.com
5 years ago
In a Genentech Redux, Roche Pays $2.4B for Rest of Foundation Medicine